Combining angiogenesis inhibition and radiotherapy: A double-edged sword

Drug Resistance Updates

Volumn 15, Issue 3, 2012, Pages 173-182

  Kleibeuker, Esther A ^a   Griffioen, Arjan W ^a   Verheul, Henk M ^a   Slotman, Ben J ^a   Thijssen, Victor L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Angiostatic therapy; Clinical trials; Combination therapy; Dose scheduling; Endothelial cells; Pre clinical trials; Radiation therapy; Toxicity; Vasculature

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BICALUTAMIDE; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MONOCLONAL ANTIBODY DC101; OXALIPLATIN; PACLITAXEL; PEMETREXED; RALTITREXED; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TOPOTECAN; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ADJUVANT CHEMORADIOTHERAPY; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLEEDING; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DUODENAL ULCER BLEEDING; ENDOTHELIUM CELL; ERYTHROCYTE; ESOPHAGUS CANCER; EXTRACELLULAR MATRIX; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GLIOSARCOMA; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMOPTYSIS; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NASOPHARYNX CANCER; NONHUMAN; NUTRIENT SUPPLY; OVARY CANCER; OVERALL SURVIVAL; OXYGEN DELIVERY DEVICE; PANCREAS CANCER; PERICYTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RECTUM CANCER; RECTUM CARCINOMA; REVIEW; SARCOMA; SENESCENCE; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; STROKE; THROMBOEMBOLISM; TISSUE OXYGENATION; TREATMENT DURATION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER;

EID: 84862664361     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2012.04.002     Document Type: Article

References (94)

1. Ahn, G.O., Brown, J.M., 2008. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13, 193-205.
2. Allavena, P., Sica, A., Solinas, G., Porta, C., Mantovani, A., 2008. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Critical Reviews in Oncology/Hematology 66, 1-9.
3. Allegra, C.J., Yothers, G., O'Connell, M.J., et al., 2011. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. Journal of Clinical Oncology 29, 11-16.
4. Arnold, A.M., Seymour, L., Smylie, M., et al., 2007. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. Journal of Clinical Oncology 25, 4278-4284.
5. Atkins, M.B., Sosman, J.A., Agarwala, S., et al., 2008. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113, 2139-2145.
6. Barcellos-Hoff, M.H., Park, C., Wright, E.G., 2005. Radiation and the microenvironment - tumorigenesis and therapy. Nature Reviews Cancer 5, 867-875.
7. Batchelor, T.T., Sorensen, A.G., di, T.E., et al., 2007. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95.
8. Baudelet, C., Ansiaux, R., Jordan, B.F., Havaux, X., Macq, B., Gallez, B., 2004. Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? Physics in Medicine & Biology 49, 3389-3411.
9. Begg, A.C., Stewart, F.A., Vens, C., 2011. Strategies to improve radiotherapy with targeted drugs. Nature Reviews Cancer 11, 239-253.
10. Bernier, J., Hall, E.J., Giaccia, A., 2004. Radiation oncology: a century of achievements. Nature Reviews Cancer 4, 737-747.
11. Bonner, J.A., Harari, P.M., Giralt, J., et al., 2006. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine 354, 567-578.
12. Camphausen, K., Moses, M.A., Beecken, W.D., Khan, M.K., Folkman, J., O'Reilly, M.S., 2001. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Research 61, 2207-2211.
13. Crane, C.H., Ellis, L.M., Abbruzzese, J.L., et al., 2006. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. Journal of Clinical Oncology 24, 1145-1151.
14. Czito, B.G., Bendell, J.C., Willett, C.G., et al., 2007. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. International Journal of Radiation Oncology, Biology, Physics 68, 472-478.
15. de Bock, K., Cauwenberghs, S., Carmeliet, P., 2011. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Current Opinion in Genetics and Development 21, 73-79.
16. Delaney, G., Jacob, S., Featherstone, C., Barton, M., 2005. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104, 1129-1137.
17. Deorukhkar, A., Krishnan, S., 2010. Targeting inflammatory pathways for tumor radiosensitization. Biochemical Pharmacology 80, 1904-1914.
18. Dewhirst, M.W., Cao, Y., Moeller, B., 2008. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Reviews Cancer 8, 425-437.
19. Dings, R.P., Loren, M., Heun, H., et al., 2007. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clinical Cancer Research 13, 3395-3402.
20. Dings, R.P., Vang, K.B., Castermans, K., et al., 2011. Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clinical Cancer Research 17, 3134-3145.
21. Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S., 2009. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239.
22. Emblem, K.E., Bjornerud, A., Mouridsen, K., et al., 2011. T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. Journal of Cerebral Blood Flow and Metabolism 31, 2054-2064.
23. Escudier, B., Bellmunt, J., Negrier, S., et al., 2010. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Journal of Clinical Oncology 28, 2144-2150.
24. Fajardo, L.F., 2005. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncologica 44, 13-22.
25. Gasparini, G., Torino, F., Ueno, T., et al., 2012. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 15, 141-150.
26. Geng, L., Donnelly, E., McMahon, G., et al., 2001. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Research 61, 2413-2419.
27. Gorski, D.H., Mauceri, H.J., Salloum, R.M., et al., 1998. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Research 58, 5686-5689.
28. Gotink, K.J., Verheul, H.M., 2010. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13, 1-14.
29. Griffioen, A.W., 2007. Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level? Trends in Cardiovascular Medicine 17, 171-176.
30. Griffioen, A.W., Molema, G., 2000. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacological Reviews 52, 237-268.
31. Han, E.S., Monk, B.J., 2007. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecologic Oncology 105, 3-6.
32. Hapani, S., Chu, D., Wu, S., 2009. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. The Lancet Oncology 10, 559-568.
33. Herbst, R.S., Takeuchi, H., Teicher, B.A., 1998. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemotherapy and Pharmacology 41, 497-504.
34. Heusschen, R., van Gink, M., Griffioen, A.W., Thijssen, V.L., 2010. MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. Biochimica et Biophysica Acta 1805, 87-96.
35. Hlushchuk, R., Riesterer, O., Baum, O., et al., 2008. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. American Journal of Pathology 173, 1173-1185.
36. Imaizumi, N., Monnier, Y., Hegi, M., Mirimanoff, R.O., Ruegg, C., 2010. Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting. PLoS One 5, e11084.
37. Jain, R.K., 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
38. Jain, R.K., Duda, D.G., Clark, J.W., Loeffler, J.S., 2006. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Reviews Clinical Oncology 3, 24-40.
39. Kamoun, W.S., Ley, C.D., Farrar, C.T., et al., 2009. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. Journal of Clinical Oncology 27, 2542-2552.
40. Kaplan, H.S., Murphy, E.D., 1949. The effect of local roentgen irradiation on the biological behavior of a transplantable mouse carcinoma; increased frequency of pulmonary metastasis. Journal of the National Cancer Institute 9, 407-413.
41. Kim, K.W., Hwang, M., Moretti, L., Jaboin, J.J., Cha, Y.I., Lu, B., 2008. Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy 4, 659-668.
42. Kirova, Y.M., Chargari, C., Amessis, M., Vernant, J.P., Dhedin, N., 2010. Concurrent involved field radiation therapy and temsirolimus in refractory mantle cell lymphoma (MCL). American Journal of Hematology 85, 892.
43. Knisely, J.P., Berkey, B., Chakravarti, A., et al., 2008. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). International Journal of Radiation Oncology, Biology, Physics 71, 79-86.
44. Lee, C.G., Heijn, M., di Tomaso, E., et al., 2000. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Research 60, 5565-5570.
45. Li, F., Sonveaux, P., Rabbani, Z.N., et al., 2007. Regulation of HIF-1alpha stability through S-nitrosylation. Molecular Cell 26, 63-74.
46. Lima, A.B., Macedo, L.T., Sasse, A.D., 2011. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 6, e22681.
47. Liu, S.K., Bham, S.A., Fokas, E., et al., 2011. Delta-like ligand 4-notch blockade and tumor radiation response. Journal of the National Cancer Institute 103, 1778-1798.
48. Lunt, S.J., Fyles, A., Hill, R.P., Milosevic, M., 2008. Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. Future Oncology 4, 793-802.
49. Matsumoto, K., Subramanian, S., Devasahayam, N., et al., 2006. Electron paramagnetic resonance imaging of tumor hypoxia: enhanced spatial and temporal resolution for in vivo pO2 determination. Magnetic Resonance in Medicine 55, 1157-1163.
50. Matsumoto, S., Batra, S., Saito, K., et al., 2011. Anti-angiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Research 71, 6350-6359.
51. Mauceri, H.J., Hanna, N.N., Beckett, M.A., et al., 1998. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394, 287-291.
52. Meng, Y., Beckett, M.A., Liang, H., et al., 2010. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Research 70, 1534-1543.
53. Milosevic, M.F., Fyles, A.W., Wong, R., et al., 1998. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 82, 2418-2426.
54. Moeller, B.J., Cao, Y., Li, C.Y., Dewhirst, M.W., 2004. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-441.
55. Moeller, B.J., Dreher, M.R., Rabbani, Z.N., et al., 2005. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8, 99-110.
56. Nieder, C., Wiedenmann, N., Andratschke, N., Molls, M., 2006. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treatment Reviews 32, 348-364.
57. Nowak-Sliwinska, P., Weiss, A., van Beijnum, J.R., et al., 2011. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. Journal of Cellular and Molecular Medicine, in press.
58. Nozue, M., Isaka, N., Fukao, K., 2001. Over-expression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer. Oncology Reports 8, 1247-1249.
59. O'Reilly, M.S., 1997. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 79, 273-294.
60. Overgaard, J., 2007. Hypoxic radiosensitization: adored and ignored. Journal of Clinical Oncology 25, 4066-4074.
61. Overgaard, J., Horsman, M.R., 1996. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Seminars in Radiation Oncology 6, 10-21.
62. Peters, N.A., Richel, D.J., Verhoeff, J.J., Stalpers, L.J., 2008. Bowel perforation after radiotherapy in a patient receiving sorafenib. Journal of Clinical Oncology 26, 2405-2406.
63. Potente, M., Gerhardt, H., Carmeliet, P., 2011. Basic and therapeutic aspects of angiogenesis. Cell 146, 873-887.
64. Pries, A.R., Cornelissen, A.J., Sloot, A.A., et al., 2009. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Computational Biology 5, e1000394.
65. Rofstad, E.K., Ruud, E.B., Mathiesen, B., Galappathi, K., 2010. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue. Clinical Cancer Research 16, 936-945.
66. Schiewer, M.J., Den, R., Hoang, D.T., et al., 2012. mTOR is a selective effector of the radiation therapy response in androgen receptor positive prostate cancer. Endocrine-related Cancer 19, 1-12.
67. Seiwert, T.Y., Haraf, D.J., Cohen, E.E., et al., 2008. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. Journal of Clinical Oncology 26, 1732-1741.
68. Semenza, G.L., 2003. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 3, 721-732.
69. Senan, S., Smit, E.F., 2007. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 12, 465-477.
70. Shrimali, R.K., Yu, Z., Theoret, M.R., Chinnasamy, D., Restifo, N.P., Rosenberg, S.A., 2010. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Research 70, 6171-6180.
71. Smith, B.D., Smith, G.L., Carter, D., Sasaki, C.T., Haffty, B.G., 2000. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. Journal of Clinical Oncology 18, 2046-2052.
72. Sofia Vala, I., Martins, L.R., Imaizumi, N., et al., 2010. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One 5, e11222.
73. Solberg, T.D., Nearman, J., Mullins, J., Li, S., Baranowska-Kortylewicz, J., 2008. Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. International Journal of Radiation Oncology, Biology, Physics 72, 918-926.
74. Suit, H.D., Sedlacek, R.S., Gillette, E.L., 1970. Examination for a correlation between probabilities of development of distant metastasis and of local recurrence. Radiology 95, 189-194.
75. Teicher, B.A., 1998. Role of angiogenesis in the response to anticancer therapies. Drug Resistance Updates 1, 59-61.
76. Teicher, B.A., Dupuis, N.P., Kusomoto, T., et al., 1994. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiation Oncology Investigations 2, 269-276.
77. Teicher, B.A., Holden, S.A., Ara, G., et al., 1995. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. International Journal of Cancer 61, 732-737.
78. Thijssen, V.L., Barkan, B., Shoji, H., et al., 2010. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Research 70, 6216-6224.
79. Thijssen, V.L., van Beijnum, J.R., Mayo, K.H., Griffioen, A.W., 2007. Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango. Current Pharmaceutical Design 13, 3576-3583.
80. Tong, R.T., Boucher, Y., Kozin, S.V., Winkler, F., Hicklin, D.J., Jain, R.K., 2004. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Research 64, 3731-3736.
81. Truman, J.P., Garcia-Barros, M., Kaag, M., et al., 2010. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One 5, e12310.
82. Tsai, M.H., Cook, J.A., Chandramouli, G.V., et al., 2007. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Research 67, 3845-3852.
83. Tufto, I., Lyng, H., Rofstad, E.K., 1996. Interstitial fluid pressure, perfusion rate and oxygen tension in human melanoma xenografts. British Journal of Cancer Supplement 27, S252-S255.
84. Urbich, C., Kuehbacher, A., Dimmeler, S., 2008. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovascular Research 79, 581-588.
85. Van de Veire, S., Stalmans, I., Heindryckx, F., et al., 2010. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178-190.
86. Verheul, H.M., Pinedo, H.M., 2007. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer 7, 475-485.
87. Vincenti, S., Brillante, N., Lanza, V., et al., 2011. HUVEC respond to radiation by inducing the expression of pro-angiogenic microRNAs. Radiation Research 175, 535-546.
88. Wachsberger, P.R., Burd, R., Marero, N., et al., 2005. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clinical Cancer Research 11, 835-842.
89. Walraven, M., Witteveen, P.O., Lolkema, M.P., van Hillegersberg, R., Voest, E.E., Verheul, H.M., 2011. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 14, 135-141.
90. Willett, C.G., Boucher, Y., di, T.E., et al., 2004. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine 10, 145-147.
91. Williams, K.J., Telfer, B.A., Brave, S., et al., 2004. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clinical Cancer Research 10, 8587-8593.
92. Williams, K.J., Telfer, B.A., Xenaki, D., et al., 2005. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiotherapy and Oncology 75, 89-98.
93. Winkler, F., Kozin, S.V., Tong, R.T., et al., 2004. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563.
94. Zips, D., Krause, M., Hessel, F., et al., 2003. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Research 23, 3869-3876.